Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

BIIB Biogen Earnings and EPS analysis

EPS in 2025 (TTM): $10.16

Last Report Period Date: Mar 31, 2025

As of July this year, based on Biogen's most recent financial report, the company's trailing twelve months EPS is $10.16. During 2024, BIIB reported a per-share earnings of $11.21, which shows a rise compared to the EPS of $8.02 recorded in 2023. Biogen's EPS for the quarterly period ending on Mar 31, 2025 came in at $1.65.

BIIB earnings history

Historical annual and quarterly earnings per share (EPS) data for Biogen
EPS (TTM)
$10.16
EPS Growth YoY (Quarterly)
-39.1%
EPS (Quarterly)
$1.65
EPS Growth (Quarterly)
-9.8%

The yearly earnings per share during 2024 was $11.21, a rise of 39.8% compared to $8.02 recorded in 2023. Over the quarter ending Mar 31, 2025, the earnings per share came in at $1.65, reflecting a 39.1% decline compared to the same quarter a year earlier. As of March 2025, the TTM EPS is $10.16. During 2023, the annual earnings per share was $8.02, representing a decrease of 61.7% compared to 2022.

BIIB EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-39.1%
EPS growth YoY
39.8%
EPS growth 3Y avg
2.4%
EPS growth 5Y avg
-18.7%

Over the past 12 months, Biogen has recorded an earnings per share growth rate of -39.1% (YoY, quarterly). Over an extended period, the company recorded an average EPS annual growth rate of 2.4% per year for the last 3 years. In the last five years, the company had an average annual EPS growth of -18.7%. A ten-year view shows that BIIB has seen an average earnings per share growth of -1% per year.

BIIB Earnings Waterfall

Breakdown of revenue, profit and net income for Biogen

BIIB Earnings vs Peers

What are the earnings of BIIB compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BIIB Biogen Inc 13.23 39.8% 2.4% -18.7%
JNJ Johnson & Johnson 17.2 -57.9% -9.7% 0.4%
PFE Pfizer Inc 18.43 273.7% -28.7% -13.2%
GILD Gilead Sciences Inc 23.28 -91.6% -57.5% -38.3%
AMGN Amgen Inc 26.88 -39.3% -9.7% -10.1%
ABBV AbbVie Inc 80.41 -12.1% -28.2% -14.7%
QGEN Qiagen NV 111.28 -74.7% -44.7% N/A
BIO Bio-Rad Laboratories Inc N/A -199.5% N/A N/A
ILMN Illumina Inc N/A -4.8% N/A N/A
SGMO Sangamo Therapeutics Inc N/A 66.9% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.